Rhode Island health care providers may no longer order the monoclonal antibodies bamlanivimab and etesevimab until further notice due to rising prevalence of the SARS-CoV-2 P.1 and B.1.351 variants, which are not susceptible to the combination therapy, the Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response announced today.

ASPR also continues to suspend distribution of bamlanivimab and etesevimab in Arizona, California, Florida, Illinois, Indiana, Massachusetts, Oregon and Washington due to spread of one or both of these variants in those states.

The Food and Drug Administration recommends providers in R.I. and these other states use the alternative monoclonal antibody therapies REGEN-COV or sotrovimab, which are likely to remain active against these variants, ASPR said. The announcement does not affect other states, but providers should monitor the frequency of the P.1 and B.1.351 variants in their region and review the fact sheets for each authorized monoclonal antibody therapy for details regarding specific variants and resistance, ASPR said.

Related News Articles

Headline
The AHA yesterday joined the U.S. Chamber of Commerce and American Medical Association in urging the 11th Circuit Court of Appeals to void a district court…
Headline
All clinicians should get vaccinated against COVID-19, encourage their staff and patients to get vaccinated, and recommend immunocompromised patients continue…
Headline
The AHA, America’s Essential Hospitals, Association of American Medical Colleges, Catholic Health Association of the United States, and Children’s Hospital…
Headline
The Centers for Disease Control and Prevention today adjusted its guidance for fully vaccinated individuals, urging indoor masking in states that are labeled…
Headline
The Health Resources and Services Administration today awarded 127 organizations a total of $121 million in American Rescue Plan Act funds to work with…
Headline
The Food and Drug Administration last week issued an emergency use authorization to Becton, Dickinson and Company for its sodium citrate blood specimen…